Table 3.
Log-additive association between SOD2 tagSNPs and ototoxicity among pediatric medulloblastoma patients at Texas Children’s Hospital (n = 71), 1987–2010
| Unadjusted model | Adjusted model2 | ||||
|---|---|---|---|---|---|
| Case1 (n = 26) | Control (n = 45) | OR (95% CI) | OR (95% CI) | FDR | |
| rs7855 | 0.86 (0.07–9.97) | 0.44 (0.03–6.63) | 0.554 | ||
| AA | 25 | 43 | |||
| AG | 1 | 2 | |||
| GG | 0 | 0 | |||
| rs5746136 | 2.04 (0.91–4.57) | 2.64 (0.98–7.11) | 0.072 | ||
| GG | 1 | 6 | |||
| AG | 9 | 9 | |||
| AA | 16 | 16 | |||
| rs2758331 | 2.04 (1.01–4.11) | 2.59 (1.09–6.15) | 0.060 | ||
| AA | 6 | 8 | |||
| AC | 16 | 16 | |||
| CC | 4 | 21 | |||
| rs4880 | 2.16 (1.06–4.38) | 3.06 (1.30–7.20) | 0.040 | ||
| TT | 3 | 18 | |||
| TC | 15 | 18 | |||
| CC | 8 | 9 | |||
SNP, single-nucleotide polymorphism; OR, odds ratio; FDR, false discover rate q-value.
1
Defined as use of a hearing aid device greater than 1 year removed from the completion of primary therapy.
2
Adjusted for age at diagnosis, gender, ethnic group, cumulative cisplatin dose, and craniospinal irradiation doses ≥34 Gy.